[A21-103] Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31
Last updated 16.09.2021
Project no.:
A21-103
Commission:
Commission awarded on 10.08.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Indication:
Adult patients with severe thrombocytopenia and chronic liver disease who are scheduled to undergo an invasive procedure
Result of dossier assessment:
Unchanged after addendum:
- Moderate or high bleeding risk of the invasive procedure: proof of considerable added benefit.
- Low bleeding risk of the invasive procedure: added benefit not proven.
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-31 | Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.